Department of Dermatology, Erasmus University Medical Center, Rotterdam, The Netherlands.
J Eur Acad Dermatol Venereol. 2023 Dec;37(12):2537-2542. doi: 10.1111/jdv.19378. Epub 2023 Aug 2.
Abrocitinib is a JAK-1 selective inhibitor registered for the treatment of moderate-to-severe atopic dermatitis (AD). Although efficacy and safety have been shown in phase 3 clinical trials, data on real-world patients with a treatment history of advanced systemics are scarce.
The objective of the study was to evaluate the effectiveness and safety of abrocitinib treatment in patients with difficult-to-treat AD in daily practice.
In this prospective observational single-centre study, all AD patients who started abrocitinib treatment in the context of standard care between April 2021 and December 2022 were included. Effectiveness was assessed using clinician- and patient-reported outcome measures. Adverse events were evaluated.
Forty-one patients were included. The majority (n = 30; 73.2%) had failed (ineffectiveness) on other targeted therapies, including JAK inhibitors (n = 14, 34%) and biologics (n = 16, 39%). Abrocitinib treatment resulted in a significant decrease in disease severity during a median follow-up period of 25 weeks (IQR 16-34). Median EASI score at baseline decreased from 14.7 (IQR 10.4-25.4) to 4.0 (IQR 1.6-11.4) at last review (p < 0.001). Median NRS itch decreased from 7.0 (IQR 5-8) to 3.0 (IQR 1-2) at last review (p < 0.001). The most frequently reported AEs included gastrointestinal symptoms (27.6%), acne (20.7%) and respiratory tract infections (17.2%). 16 (39%) patients discontinued abrocitinib treatment due to ineffectiveness, AEs or both (41.2%, 41.2% and 11.8%, respectively).
Abrocitinib can be an effective treatment for patients with moderate-to-severe AD in daily practice, including non-responders to other targeted therapies.
阿巴西普是一种 JAK-1 选择性抑制剂，已注册用于治疗中重度特应性皮炎（AD）。尽管在 3 期临床试验中已显示出疗效和安全性，但关于具有先进系统治疗史的真实世界患者的数据却很少。
本研究的目的是评估阿巴西普治疗日常实践中治疗困难的 AD 患者的有效性和安全性。
在这项前瞻性观察性单中心研究中，纳入了 2021 年 4 月至 2022 年 12 月期间在标准治疗背景下开始阿巴西普治疗的所有 AD 患者。使用临床医生和患者报告的结局测量来评估疗效。评估不良事件。
共纳入 41 例患者。大多数患者（n=30；73.2%）在其他靶向治疗中失败（无效），包括 JAK 抑制剂（n=14，34%）和生物制剂（n=16，39%）。在中位随访 25 周（IQR 16-34）期间，阿巴西普治疗可显著降低疾病严重程度。基线时 EASI 评分中位数从 14.7（IQR 10.4-25.4）降至最后一次评估时的 4.0（IQR 1.6-11.4）（p<0.001）。NRS 瘙痒评分中位数从 7.0（IQR 5-8）降至最后一次评估时的 3.0（IQR 1-2）（p<0.001）。最常报告的 AE 包括胃肠道症状（27.6%）、痤疮（20.7%）和呼吸道感染（17.2%）。16 例（39%）患者因无效、AE 或两者均因停止阿巴西普治疗（分别为 41.2%、41.2%和 11.8%）。
阿巴西普在日常实践中可有效治疗中重度 AD 患者，包括对其他靶向治疗无应答的患者。
